Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment

Blood Adv. 2023 Dec 26;7(24):7581-7584. doi: 10.1182/bloodadvances.2023011428.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bortezomib / adverse effects
  • Dexamethasone / adverse effects
  • Humans
  • Multiple Myeloma* / complications
  • Multiple Myeloma* / diagnosis
  • Multiple Myeloma* / drug therapy
  • Renal Insufficiency* / complications
  • Renal Insufficiency* / diagnosis
  • Thalidomide / adverse effects

Substances

  • pomalidomide
  • Bortezomib
  • Thalidomide
  • Dexamethasone